GlaxoSmithKline Sees First-Quarter Profit Fall -- Update
April 27 2016 - 8:05AM
Dow Jones News
By Denise Roland
LONDON-- GlaxoSmithKline PLC said net profit fell in the first
quarter of 2016, due to a tough year-earlier comparison which was
boosted by proceeds from its three-way transaction with Novartis
AG, without that effect, profit rose on cost savings from the same
deal.
The U.K.-based pharmaceuticals company said net income for the
three months ended March 31 was GBP282 million ($410 million), a
fraction of the GBP8.1 billion reported a year earlier.
Core net income, which strips out one-time gains and
impairments, increased 15% to GBP959 million, from GBP834 million a
year ago. Revenue rose 11% to GBP6.2 billion, up from GBP5.6
billion a year ago. Glaxo beat expectations on both fronts:
analysts were expecting core net income of GBP894 million and
revenue of GBP6 billion.
Core earnings per share, Glaxo's preferred measure of profit,
increased 14% to 19.8 pence. The weakness of the pound versus the
dollar boosted Glaxo's results--stripping out exchange rate
movements, revenue and core earnings per share increased 8%.
Glaxo also provided more clarity on its 2016 outlook, saying it
expected core earnings per share to grow 10%-12% at constant
exchange rates. Previously, it had guided for a double-digit
increase. The company also confirmed plans to pay a full-year
dividend of 80p.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
April 27, 2016 07:50 ET (11:50 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024